Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.
Elena AtanasovaDragana MilosevicSvetlana BornschleglKaren P KruckerEapen K JacobEva M Carmona PorqueraDagny K AndersonAshley M EganAndrew H LimperAllan B DietzPublished in: Stem cell research & therapy (2022)
Our results indicate that there are no differences in aMSC properties from IPF patients and HC, suggesting that autologous aMSCs may be an acceptable option for IPF therapy. The altered immune system of IPF patients may be a valuable biomarker for disease burden and monitoring therapeutic response.